Related Experiment Video
Updated: May 29, 2026

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides (CHIPS)
Published on: June 20, 2014
New green synthesis and formulations of acyclovir prodrugs
Rubén de Regil-Hernández1, Fernando Martínez-Lagos, Amalia Rodríguez-Bayón
1Servicio de Biotransformaciones Industriales, Parque Científico de Madrid, Santiago Grisolía 2, Parque Tecnológico de Madrid, Tres Cantos, 28760 Madrid, Spain.
Abstract:
Different green synthesis of alkyl esters of acyclovir (acyclovir prodrugs) is described. Hexanoic, decanoic, dodecanoic and tetradecanoic acyclovir esters were synthesized reacting acyclovir and the respective acid anhydride in dimethyl sulfoxide (DMSO), in solvents from renewable sources and without solvent (T=30 °C). Yields in prodrugs after 10 min of reaction were >95% using DMSO as solvent. The purification methodology was very simple, shorter and greener than previously described. The biosolvent, N,N-dimethylamide of decanoic acid, let us to obtain >95% yield at 24 h. This oily biosolvent is not dermotoxic and the reaction crude can directly be used in topic formulations. Syntheses without solvent proceeded successfully for acyclovir esters. Indeed, dodecanoate and tetradecanoate yielding >98% conversion of reactants in 30 min. In spite of requiring mild temperature (65 °C), substrate molar ratios were lowered to 1 : 1, thus conducing to a more efficient use of raw materials. The synthetic procedures were scaled up to a 300 g batch (yield 98-99% isolated ester). These esters can be used as acyclovir prodrugs in topic formulations. The esters release from an oil/water micro-emulsion and a hydrogel formulation were tested with good results.
More Related Videos
Related Concept Videos
Antiviral Nucleoside Inhibitors
Prodrugs
Prodrugs help overcome...
Inhibitors of Viral Protein Synthesis
Clinically Relevant Drug Product Specifications: Methods of Establishment
Inhibitors Of Virion Release
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

